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Introduction: Nutritional support is pivotal in patients submitted to hematopoietic stem cell
transplantation. Nutritional status has been associated with time of engraftment and infec-
tion  rates. In order to evaluate the association between nutritional parameters and clinical
outcomes after transplantation a cohort of transplant patients was retrospectively evalu-
ated.
Methods: All 50 patients transplanted between 2011 and 2014 were included. The nutri-
tional status before transplantation, ten days after transplantation and before discharge
was  assessed including anthropometry, body mass index, albumin, prealbumin and total
urinary nitrogen.
Results: The median follow-up time was 41 months and the median age of patients was 41
years.  Thirty-two underwent allogeneic and 18 autologous transplants. Diagnoses included
acute leukemias (n = 27), lymphoma (n = 7), multiple myeloma (n = 13), and aplastic anemia
(n  = 3). Thirty-seven patients developed mucositis (three Grade 1, 15 Grade 2, 18 Grade 3 and
one  Grade 4), and twenty-two allogeneic, and ﬁve autologous transplant patients required
total  parenteral nutrition. Albumin and total urinary nitrogen were associated with length of
hospital stay and platelet and neutrophil engraftment. None of the nutritional parameters
evaluated were associated with overall survival. Non-relapse mortality was 14% and overall
survival was 79% at 41 months of follow-up.
Conclusions: After hematopoietic stem cell transplantation, high catabolism was associated
with  longer length of hospital stay, the need of total parenteral nutrition and platelet and
neutrophil engraftment times. Nutritional parameters were not associated with overall sur-
vival.
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Table 1 – Patient characteristics.
Gender – n (%)
Male 33 (66)
Female 17 (34)
Median Age – years (range) 41 (17–67)
Diagnosis – n (%)
Acute leukemia 26 (52)
Myelodysplastic syndrome 1 (2)
Lymphoma 7 (14)
Myeloma 13 (26)
Aplastic anemia 3 (6)
Average length of stay – days (range) 32 (19–109)
Type of transplant – n (%)
Autologous 18 (36)
Allogeneic 32 (64)
Related 20 (63)
Unrelated 9 (28)
Cord 3 (9)
Conditioning – n (%)
Myeloablative 42 (84)8  rev bras hematol he
Introduction
Nutritional support is one of the most important issues
in the management of patients who undergo hematopoi-
etic stem cell transplantation (HSCT).1,2 Many  factors induce
changes in the metabolism during HSCT3 including high-
dose chemotherapy and total body irradiation, mucositis
with painful ulcers, diminished ingestion, nausea, vomi-
ting and diarrhea.2 Allogeneic HSCT (allo-HSCT) usually
produces the greatest changes in body composition and
muscle metabolism, infections and acute graft-versus-host
disease (aGVHD).4,5
Malnutrition has been identiﬁed as a major challenge in
HSCT. Furthermore in malnourished (under and overweight)
patients, studies have shown a higher risk of complications:
changes in the body composition resulting in electrolyte
imbalance and impairment of the immune system (both asso-
ciated with longer engraftment time) and most of all, higher
non-relapse mortality rates in the immediate post-transplant
period.6–9
Energy requirements after transplantation usually increase
by 30–50%, which is why nutritional support has been sug-
gested as a contributing factor to an improved engraftment
time and lower risk of infection during the neutropenic
stage.9–11 Parenteral nutrition is supportive care, which main-
tains the nutritional status of patients during the transplant
process.
There are now many  nutritional parameters available in
the nutritional assessments of cancer patients and speciﬁcally
HSCT patients. This paper presents the impact of pre-HSCT
and post-HSCT biochemical and anthropometric evaluations
on the clinical outcomes of HSCT. Thus, the aim of this
study was to identify any associations between several nutri-
tional parameters and the incidence of gastrointestinal and
hepatic aGVHD, infectious complications, length of hospital
stay, delayed neutrophil or platelet engraftment and overall
survival (OS).
Methods
Patients
All patients who  underwent autologous HSCT (auto-HSCT)
and allo-HSCT between 2011 and 2014 at the Pontiﬁcia Uni-
versidad Católica de Chile were included in this study. Data
were collected from the electronic and paper charts as well as
the HSCT program database. The study was approved by the
institutional review board.
Transplant  procedure
After the decision to transplant had been made, patients
underwent a number of evaluations to determine their suit-
ability for transplantation and, when apt, auto-HSCT or
allo-HSCT was performed. Conditioning regimens for the
HSCT are shown in Table 1.
In sibling and matched unrelated HSCT, prophylaxis for
graft-versus-host disease (GVHD) was made with cyclosporineReduced intensity 8  (16)
and methotrexate or tacrolimus and methotrexate. In cord
blood HSCT, GVHD prophylaxis was made with cyclosporine
and mycophenolate mofetil.
Prophylaxis against infectious diseases for all the patients
included levoﬂoxacin (500 mg  q.d.) starting on Day −1 until
neutrophil recovery or febrile neutropenia, acyclovir (400 mg
t.i.d) starting on Day −1 until Day +365, ﬂuconazole (200 mg
q.d.) starting on Day −1 until Day +100 and sulfamethoxazole
trimethoprim (q.d. 3 times a week) starting with neutrophil
recovery until Day +365. Similarly, all patients were kept in
isolated rooms with high efﬁciency particulate air ﬁlters and
positive pressure during the neutropenic phase of the trans-
plant. Patients were given a neutropenic diet and received
intravenous ﬁlgrastim 300 g starting on Day +5 until neu-
trophil engraftment.
Nutritional  evaluation
A nutritional evaluation was conducted at the time of
HSCT, ten days after HSCT and before patient discharge.
Pre-transplant assessments included body mass index
(BMI), anthropometry, and measurements of the albu-
min, prealbumin and total urinary nitrogen (TUN) levels.
Clinical and laboratory variables including cell counts,
hematological condition and conditioning regimens were
recorded.
Post-transplant assessment included BMI, albumin, preal-
bumin, TUN and type of nutritional support [oral, oral plus
supplement, enteral nutrition or total parenteral nutrition
(TPN)].
Grip strength was measured using a Jamar analogue hand
dynamometer with participants seated in the upright posi-
tion, their elbow by their side and ﬂexed at right angles, with
neutral wrist position. The best of three grip strength tests was
calculated. This measurement was extrapolated to theoretical
85 percentile tables by gender and age.
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MI  was calculated according to Hannan.12 BMI < 20 kg/m2
as considered underweight, between 20–25 kg/m2 normal,
5–30 kg/m2 overweight and >30 kg/m2 obese. Prealbumin was
uantiﬁed using the nephelometry method with normal val-
es between 18 and 38 mg/dL, albumin was quantiﬁed using
he colorimetric method with normal values between 3.5 and
.0 mg/dL and 24-h TUN was assessed using the Kjeldahl
ethod. Patients who  required TPN were prescribed for a spe-
iﬁc number of days. Mucositis (Grade 1 to 4) and infectious
omplications (Grade 1 to 5) were graded according to the
ational Health Institute and Common Terminology Criteria
or Adverse Events v 4.03.13 Acute GVHD (hepatic and intesti-
al) was graded according to the International Bone Marrow
ransplant Registry (IBMTR) scale.14 Time to neutrophil and
latelet engraftment was deﬁned according to standard def-
nitions: neutrophil count >500 cells/L for three consecutive
ays and platelet count >50,000 cells/L for seven consecutive
ays without the patient requiring transfusions.
tatistical  analysis
tatistical analysis was performed using the Statistical
ackage for the Social Sciences (SPSS) software (Version 20;
hicago, IL, USA). Results are presented as mean values. The
NOVA test was used to compare three mean values of the
valuations performed before the transplant, ten days after
ransplant and at discharge and the t-test to compare two
Table 2 – Conditioning regimens.
Myeloablative
regimen
Type  of HSCT n (%) Indicatio
Cy/TBI allo 21 (42) Acute
leukemia
Mel 200 auto 12 (24) Myeloma
BEC auto 4 (8) Lymphom
Cy/ATG/MP allo 2 (4) Aplastic
anemia
Flu/Cy/TBI allo/cord 3 (6) acute
leukemia
Reduced intensity
regimens
Type of HSCT n (%) Indicatio
Flu/Mel allo 2 (4) Lymphom
Flu/Cy/TBI allo 5 (10) Acute
Leukemia
Mel 140 auto 1 (2) Myeloma
HSCT: hematopoietic stem cell transplantation; allo: allogeneic; auto: au
anti-thymocyte globulin; MP: methylprednisolone.. 2 0 1 6;3  8(1):7–14 9
means (auto-HSCT vs. allo-HSCT). Multivariate analysis used
the Spearman coefﬁcient. BMI, dynamometry, albumin, pre-
albumin, TUN, triglycerides, time to platelet and neutrophil
engraftment, length of hospital stay and OS were considered
continuous variables and the need of TPN, aGVHD and pres-
ence of mucositis, categorical variables. The Cox Proportional
Hazards test was used to estimate the OS.15 OS and non-
relapse mortality were analyzed by the Kaplan–Meier method.
Statistical signiﬁcance was set for p-values <0.05.
Results
Characteristics  of  patients  and  the  hematopoietic  stem  cell
transplantation  procedure
Fifty patients transplanted between 2011 and 2014 were
analyzed. Patient characteristics are shown in Table 1. Thirty-
three (66%) were men  and seventeen (34%) were women. The
average age was 41 years (range: 17–67 years). In all, 32 allo-
HSCT and 18 auto-HSCT were performed. Indications for HSCT
were acute leukemias in 26 patients (52%), multiple myeloma
in 13 (26%), lymphoma in seven (14%), severe aplastic ane-
mia  in three (6%) and myelodysplastic syndrome in one (2%).
The average length of hospital stay was 32 days (range: 19–109
days).
Conditioning regimens (Table 2) were myeloablative in 42
cases (84%) and reduced intensity in eight cases (16%). The
median follow-up time was 41 months (range: 2–83 years).
n Therapy Dose Days before HSCT
TBI
Cy
1320 cGy total
60 mg/kg
5–2
7–6
 Melphalan 200 mg/m2 2
a Carmustine
Etoposide
Cy
300 mg/m2
200 mg/m2
twice a day
60 mg/kg
6
6–4
6–3
Cy
ATG
MP
50  mg/kg
2.5 mg/kg
250 mg/m2
twice a day
5–2
4–1
4–1
Fludarabine
Cy
TBI
25  mg/m2
60 mg/kg
1320 cGy total
8–6
7–6
4–1
n Therapy Dose Days before HCT
a Fludarabine
Melphalan
30 mg/m2
70 mg/m2
8–4
3–2
Fludarabine
Cy
TBI
40  mg/m2
50 mg/kg
200 cGy
6–2
6
1
 Melphalan 140 mg/m2 2
tologous; TBI: total body irradiation; Cy: cyclophosphamide; ATG:
10  rev bras hematol hemoter. 2 0 1 6;3  8(1):7–14
Table 3 – Nutritional assessment comparing allogeneic and autologous hematopoietic stem cell transplantation at
different time points.
Parameter Allo
Mean (range)
Auto
Mean  (range)
p-Value
At admission
BMI – kg/m2 27.0 (22.7–31.3) 27.0 (23.8–30.2) 0.99
DNM – kg 74.0 (48.1–99.9) 95.2 (66.9–123.5) 0.053
Albumin – mg/dL 4.12 (3.8–4.4) 4.12 (3.8–4.4) 0.99
Prealbumin – mg/dL 25.37 (19.8–30.9) 25.22 (18.9–31.5) 0.93
TUN – g/24 h 18.77  (9.9–27.5) 19.43 (13.2–25.6) 0.80
TG – mg/dL 171  (68–274) 103 (28–152) 0.07
Ten days after transplant
BMI – kg/m2 19.04 (8.0–30.0) 15.33 (3.7–26.8) 0.27
DNM – kg 72.09 (51.0–93.1) 70.85 (50.0–91.6) 0.89
Albumin – mg/dL 3.23 (2.2–3.9) 3.42 (2.9–3.9) 0.08
Prealbumin – mg/dL 17.74 (9.6–25.8) 19.99 (11.1–28.7) 0.29
TUN – g/24 h 21.63 (14.6–28.6) 22.96 (15.2–30.7) 0.56
TG – mg/dL 263 (138–387) 111 (49–173) 0.014
Before discharge
BMI – kg/m2 N/D N/D
DNM – kg N/D N/D
Albumin – mg/dL 3.43 (2.9–3.9) 3.53 (3.1–3.9) 0.52
Prealbumin – mg/dL 23.21 (13.7–32.6) 21.26 (15.6–26.8) 0.54
TUN – g/24 h 23.25 (12.9–33.5) 21.21 (14.5–27.9) 0.56
TG – mg/dL 331 (148–514) N/D
amoAllo: allogeneic; Auto: autologous; BMI: body mass index; DNM: dyn
available.
Nutritional  status  before  and  after  hematopoietic  stem  cell
transplantation
At admission for HSCT, there were no signiﬁcant differences
regarding nutritional parameters between the groups of allo-
HSCT and auto-HSCT patients (Table 3). After transplantation
only the triglycerides levels were signiﬁcantly higher in the
allo-HSCT Group compared to auto-HSCT Group. The other
parameters were similar between both groups (Table 3).
On combining the HSCT groups, there were signiﬁcant
reductions in the BMI, and prealbumin and albumin levels
in the post-transplant period compared to the pre-transplant
period. Triglyceride levels were signiﬁcantly higher in the
post-transplant assessment. No differences in TUN and
dynamometry were found between the three evaluations
(Table 4).
Considering the type of HSCT, albumin levels decreased
signiﬁcantly in both the allo-HSCT and auto-HSCT Groups
after transplantation. However, the reduction in prealbumin,
Table 4 – Nutritional assessment before transplant, 10 days afte
Parameter Before transplant
Mean (range) M
BMI (kg/m2) 26.9 (20.9–34.6) 26
DNM (kg) 79.7 (24.3–142.0) 72
Albumin (mg/dL) 4.1 (3.5–4.9) 3
Pre-albumin (mg/dL) 25.4 (14.6–35.5) 18
TUN g/24 h 18.2 (4.0–44.6) 22
TG (mg/dL) 148.7 (40–465) 235
BMI: body mass index; DNM: dynamometry; TUN: total urinary nitrogen; Tmetry; TUN: total Urinary Nitrogen; TG: triglycerides; N/D: no data
as well as the increase in triglyceride levels, were only signif-
icant in the allo-HSCT group, while a signiﬁcant drop in BMI
was only seen in the auto-HSCT group (Table 5).
Post-transplant  complications
Considering all patients, 37 (74%) developed mucositis [allo-
HSCT: n = 24 (75%) and auto-HSCT: n = 13 (72%); p-value <0.05].
According to the degree of mucositis three patients had Grade
1, 15 patients Grade 2, 18 patients Grade 3 and one had Grade 4
(Figure 1). Of the 37 patients with mucositis, 27 (73%) required
TPN [allo-HSCT: n = 22 (81%) and auto-HSCT: n = 5 (19%)] and
10 (27%) some other kind of nutritional support. According
to the type of transplant, 28% (5/18) of auto-HSCT and 69%
(22/32) of allo-HSCT patients required TPN. Figure 2 shows
the distribution of nutritional support in the different groups.
Eight patients without mucositis also required TPN because of
severe nausea and vomiting.
r transplant and at discharge.
Day  +10
ean (range)
Before  discharge
Mean (range)
p-Value
.1 (20.0–34.7) N/D <0.01
.5 (33.0–109.0) N/D 0.9
.3 (2.2–4.0) 3.5 (2.0–4.4) <0.01
 (7.2–34.5) 21.9 (10.9–50.4) <0.01
.1 (9.9–41.4) 22.6 (9.0–50.0) 0.1
 (46–557) 324.8 (96–863) <0.01
G: triglycerides; N/D: no data available.
rev bras hematol hemoter. 2 0 1 6;3  8(1):7–14 11
Table 5 – Nutritional assessment before and after hematopoietic stem cell transplantation according to the type of
transplantation.
Parameter Before Day +10 At discharge p-Value
Allogeneic
BMI (kg/m2) 26.6 25.8 N/D 0.13
DNM (kg) 76.1 74.5 N/D 0.85
Albumin (mg/dL) 4.1 3.25 3.4 <0.01
Pre-albumin (mg/dL) 25.6 15.7 23.2 0.01
TUN g/24 h 18.9 21.5 23.2 0.19
TG (mg/dL) 172.5 255.5 331.8 <0.05
Autologous
BMI (kg/m2) 27.3 26.3 N/D  <0.05
DNM (kg) 89.7  69 N/D 0.6
Albumin (mg/dL) 4.16 3.4 3.5 <0.01
Pre-albumin (mg/dL) 25.2 20.5 21.2 0.054
TUN g/24 h 17.2 23.9 21.2 0.39
TG (mg/dL) 111 103 272.5 0.072
Results shown as means.
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support in HSCT patients. Nutritional impairment is signif-BMI: body mass index; DNM: dynamometry 85% standard for age a
available.
Considering the 32 allo-HSCT patients, nine (28%) devel-
ped intestinal aGVHD (ﬁve patients submitted to unrelated
SCT and four to related HSCT) and 23 (72%) did not develop
ntestinal aGVHD. The severity was Grade II-IV in ﬁve (56%)
nd Grade III-IV in four (44%). The average time from HSCT to
GVHD was 34 days (range: 16–80 days). Overall, 69% (22/32) of
he allo-HSCT patients required TPN. All of the patients who
eveloped intestinal aGVHD required TPN and 57% (13/23) of
he patients without intestinal GVHD required TPN, mainly
ue to anorexia.
The 41-month OS was 79% (auto-HSCT: 81%; allo-HSCT:
5%; p-value = NS). The non-relapse mortality rate (2 auto-
SCT and 4 allo-HSCT) was 12% at 41 months (11% auto-HSCT
nd 13% allo-HSCT; p-value = NS).
ultivariate  analysisn the multivariate analysis, none of the pre-HSCT nutri-
ional parameters was associated with transplant outcomes.
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igure 1 – Distribution of mucositis according to grade and
ype of hematopoietic stem cell transplantation.
uto: autologous hematopoietic stem cell transplantation;
llo: allogeneic hematopoietic stem cell transplantation.ender; TUN: total urinary nitrogen; TG: triglycerides; N/D: no data
However, several post-HSCT nutritional parameters were sta-
tistically associated with transplant outcomes. Speciﬁcally,
ten days after transplant, albumin was associated with length
of hospital stay and time to platelet engraftment; TUN was
correlated with time to platelet engraftment and days of TPN
with length of hospital stay, time to neutrophil engraftment
and time to platelet engraftment. Only TUN was associated
with time to neutrophil engraftment in the pre-discharge eval-
uation. Finally, OS was not affected by any variable in the
multivariate analysis (Table 6).
Discussion
This is the ﬁrst study from Chile to report on nutritionalicant after transplantation16 and is associated with worse
outcomes.17 Malnourishment increases the risk of death,
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Type of nutritional support
 TPN EN
Auto n=18
Allo n=32
Figure 2 – Type of nutritional support required.
auto: autologous hematopoietic stem cell transplantation;
allo: allogeneic hematopoietic stem cell transplantation;
NS: nutritional supplements; TPN: total parenteral
nutrition; EN: enteral nutrition.
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Table 6 – Signiﬁcance (p-values) by multivariate analysis of factors potentially associated with complications of
hematopoietic stem cell transplantation.
Factor HCT complications
aGVHD LOS IC TNE TPE OS
BMI before HSCT 0.444 0.277 0.326 0.25 0.249 0.925
Albumin after HSCT 0.738 0.463 0.871 0.36 0.322 0.689
Pre-albumin before HSCT 0.765 0.199 0.639 0.128 0.054 0.819
TUN before HSCT 0.625 0.052 0.786 0.397 0.171 0.613
BMI after HSCT 0.057 0.149 0.995 0.342 0.303 0.863
Albumin after HSCT 0.152 0.012 0.835 0.271 0.015 0.822
Pre-albumin after HSCT 0.507 0.062 0.797 0.167 0.065 0.391
TUN after HSCT 0.945 0.13 0.503 0.087 0.026 0.932
Days of TPN 0.834 0.001 0.062 0.002 0.001 0.159
Albumin before d/c 0.295 0.125 0.653 0.161 0.193 0.358
Pre-albumin before d/c 0.073 0.827 0.69 0.350 0.309 0.297
TUN before d/c 0.165 0.304 0.084 0.029 0.344 0.556
aGVHD: acute graft versus host disease; LOS: length of hospital stay; IC: infectious complications; TNE: time to neutrophil engraftment; TPE:
time to platelet engraftment; OS: overall survival; HSCT: hematopoietic stem cell transplantation; BMI: body Mass Index; TUN: total urinary
nitrogen; TPN: total parenteral nutrition; d/c: discharge.
mucositis, aGVHD and infectious complications in patients
submitted to HSCT.9,17,18
Several studies have addressed the topic of speciﬁc
nutritional parameters in HSCT, with discordant ﬁndings.
Schulte et al., without demonstrating any association between
BMI  and transplant complications, reported a signiﬁcant
decrease in BMI  after HSCT, which reverted one year after
transplantation.10 Other authors have identiﬁed low pre-
transplant BMI  as an independent risk factor for mortality.19–22
Urbain et al. showed that aGVHD and anorexia during trans-
plant were associated with signiﬁcant reductions in BMI in
an allo-HSCT cohort.9 This study found an overall drop in BMI
after HSCT, with statistical signiﬁcance only for the auto-HSCT
Group.
When considering other parameters, the study of Schulte
et al. showed a signiﬁcant reduction in prealbumin levels
at Day +14 and +28 after HSCT.10 In the current study, this
reduction was noticed even before, at Day +10, and persisted
until patient discharge. Albumin levels showed a signiﬁcant
reduction in the same period irrespective of the type of HSCT,
which correlated with both a longer length of hospital stay and
platelet engraftment time.
The differences found between allo-HSCT and auto-HSCT
may suggest a higher degree of catabolism in the allo-HSCT
setting. Speciﬁcally, this study observed that earlier in the
course of HSCT, the TUN levels tend to be higher after auto-
HSCT compared to allo-HSCT. However, before discharge TUN
was higher, albeit not signiﬁcantly, in the allo-HSCT Group
than the auto-HSCT Group. Moreover, albumin levels can
change in acute renal failure and during the use of transfusion
support, which is very common in this kind of patient.23,24 A
study of Underzo et al.25 showed that after TPN, albumin levels
after HSCT did not change over one week but prealbumin lev-
els did, which makes this variable a more  accurate parameter
for diet and nutritional assessments. Together with prealbu-
min, research has shown decreases of other parameters after
HSCT such as transferrin and retinol binding protein that
might predict malnutrition in allo-HSCT and auto-HSCT.26 Inthis study, higher TUN levels were associated with slower
neutrophil and platelet engraftment. This may suggest that
higher TUN levels are a surrogate of more  severe infectious
complications, which could be associated to delayed engraft-
ment time. Research failed to show an association between
nutritional support and time to neutrophil engraftment.27,28
However, a study by Habjibabaie et al. suggested that BMI, but
not TUN, was inversely correlated with the neutrophil engraft-
ment time.29
When considering complications after HSCT, the incidence
of mucositis reported in this study was 74%, similar to the
incidence of 70% reported in the literature.30 Days of TPN cor-
related with the length of hospital stay and time to platelet
and neutrophil engraftment.
None of the nutritional factors analyzed at different time
points including BMI, albumin, prealbumin, TUN and TPN,
were associated with OS in this study, and survival rates were
similar between allo-HSCT and auto-HSCT patients, possibly
due to the early nutritional support provided to all patients
and the small number of patients analyzed which precluded
statistically signiﬁcant differences. The high mortality rate in
auto-HSCT patients is possibly associated with the low num-
ber of this type of patients included in this study.
This research was unable to demonstrate any association
between TPN and a higher rate of intestinal aGVHD. However,
there are possible explanations for the association between
mucositis, aGVHD and TPN that have been suggested before.
Mucosa-associated lymphoid tissue (MALT), while normally
acting as an immunological barrier, may suffer severe damage
during conditioning for HSCT. The subsequent bacterial and
toxin translocation may act as a potent inﬂammatory stim-
ulus for the development of acute aGVHD.31,32 As shown by
Mattsson et al., the oral feeding route seems to have a protec-
tive role against the development of GVHD.33 In their study of
231 patients submitted to myeloablative conditioning, these
authors found a cumulative incidence of 39% of Grade II to
IV aGVHD in patients who did not receive any oral nutrition
for nine or more days (13 patients). However, in 144 patients
oter.
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ith oral intake, there was a cumulative incidence of only
% of aGVHD. In the current study, all of the patients with
astrointestinal aGVHD required TPN and less than half of
he patients without intestinal aGVHD required TPN, mainly
or anorexia. However, due to the small number of patients
ith aGVHD no conclusions can be reached regarding the
ssociation between aGVHD and nutritional support. TPN has
een associated with intestinal atrophy and enhanced expres-
ion of interferon gamma,  while local levels of cytokines that
rotect from GVHD, such as IL-4 and IL-10, usually show a
igniﬁcant decrease in patients using this type of nutritional
upport.34 Furthermore, many  studies in critical patients have
onsistently shown a higher incidence of infectious compli-
ations in TPN versus oral/enteral nutrition, which may be
nother possible link between the feeding route and compli-
ations such as mucositis and aGVHD.35
In the current series, the majority of patients requiring
utritional support received TPN. Controversy exists on the
est nutritional support after transplantation. A study by Szel-
ga et al.36 showed that compared to oral nutrition, TPN
as not associated with OS or hematopoietic recovery and
ength of hospitalization but was associated with a longer use
f diuretics, more  hyperglycemia and more  catheter-related
omplications. Recent studies have suggested that early
nteral support could be associated with better outcomes
ompared to TPN, including faster engraftment times.37,38
owever up to 90% of the patients undergoing myeloabla-
ive allo-HSCT will still receive TPN.39 In the current series,
ne-third of the auto-HSCT and two thirds of the allo-HSCT
eceived TPN.
The main limitation of this study is its retrospective nature,
hich precludes the investigation of causative associations
etween variables and outcomes. However, this study identi-
es some variables that should be considered to predict the
volution of patients during the acute phases of HSCT, and to
evelop more  precise ways to assess nutritional status.
onclusions
his study shows that allo-HSCT and auto-HSCT patients
ecome signiﬁcantly hypercatabolic during the acute phase
f transplants and the majority will develop mucositis requir-
ng nutritional support early in the course of the transplant
rocess. Of all the variables analyzed, albumin and TUN were
ssociated with clinical outcomes. OS was not associated with
ny nutritional parameter.
Since this is not a comparative study, we  cannot predict the
utcome of patients without appropriate nutritional support.
owever due to the frequency and severity of mucositis and
he degree of catabolism it seems reasonable to deliver appro-
riate nutritional support although the best source is still
nder study, with studies suggesting advantages of enteral
utrition over TPN.onﬂicts  of  interest
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